334 related articles for article (PubMed ID: 15752)
1. Clinical pharmacokinetics of sulphasalazine.
Das KM; Dubin R
Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
3. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
Cowan GO; Das KM; Eastwood MA
Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
[TBL] [Abstract][Full Text] [Related]
4. Sulphasalazine: a review of 40 years' experience.
Watkinson G
Drugs; 1986; 32 Suppl 1():1-11. PubMed ID: 2877847
[TBL] [Abstract][Full Text] [Related]
5. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.
Schröder H; Evans DA
Gut; 1972 Apr; 13(4):278-84. PubMed ID: 4402420
[TBL] [Abstract][Full Text] [Related]
6. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
[TBL] [Abstract][Full Text] [Related]
7. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
Taggart AJ; McDermott B; Delargy M; Elborn S; Forbes J; Roberts SD; Ahnfelt NO
Scand J Rheumatol Suppl; 1987; 64():29-36. PubMed ID: 2893450
[TBL] [Abstract][Full Text] [Related]
9. Azo reduction of sulphasalazine in healthy volunteers.
Houston JB; Day J; Walker J
Br J Clin Pharmacol; 1982 Sep; 14(3):395-8. PubMed ID: 6127096
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and biochemical actions of sulphasalazine.
Hoult JR
Drugs; 1986; 32 Suppl 1():18-26. PubMed ID: 2877850
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
Garg GP; Cho CH; Ogle CW
Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
[TBL] [Abstract][Full Text] [Related]
12. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.
Pullar T; Capell HA
Drugs; 1986; 32 Suppl 1():54-7. PubMed ID: 2877854
[TBL] [Abstract][Full Text] [Related]
13. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
[TBL] [Abstract][Full Text] [Related]
14. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.
Shaffer JL; Kershaw A; Houston JB
Br J Clin Pharmacol; 1986 Apr; 21(4):431-5. PubMed ID: 2871853
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
[TBL] [Abstract][Full Text] [Related]
16. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
Bird HA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
Allgayer H; Kruis W; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
[TBL] [Abstract][Full Text] [Related]
18. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
Pullar T; Hunter JA; Capell HA
Ann Rheum Dis; 1985 Dec; 44(12):831-7. PubMed ID: 2867746
[TBL] [Abstract][Full Text] [Related]
19. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects.
Di Paolo MC; Paoluzi OA; Pica R; Iacopini F; Crispino P; Rivera M; Spera G; Paoluzi P
Dig Liver Dis; 2001 Oct; 33(7):563-9. PubMed ID: 11816545
[TBL] [Abstract][Full Text] [Related]
20. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
Ashworth M; Arthur M; Turmer AD; Smith PR
Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
